Dysbiosis in Human Urinary Microbiota May Differentiate Patients with a Bladder Cancer
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms251810159 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Julie A Vendrell und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de Biologie des Tumeurs Solides, Département de Pathologie et Oncobiologie, CHU Montpellier, Université de Montpellier, 34295 Montpellier…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Dysbiosis, Microbiota, RNA, Ribosomal, 16S. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Recent interest in noninvasive diagnostic approaches has highlighted the potential of urinary microbiota as a novel biomarker for bladder cancer. This study investigated the urinary microbiota of 30 bladder cancer patients and 32 healthy controls using a specific NGS protocol that sequences eight hypervariable regions of the 16S rRNA gene, providing detailed insights into urinary microbiota composition. The relative abundance of microbial compositions in urine samples from cancer patients and healthy controls was analyzed across various taxonomic levels. No notable differences were highlighted at the phylum, class, order, and family levels. At the genus level, 53% of detected genera were represented in either cancer patients or healthy controls. Microbial diversity was significantly lower in cancer patients. The differential analysis identified five genera, Rhodanobacter, Cutibacterium, Alloscardovia, Moryella, and Anaeroglobus, that were significantly more abundant in cancer patients. Notably, Rhodanobacter was present in 20 cancer samples but absent in healthy controls. Conversely, 40 genera, including Lactobacillus, Propionibacterium, and Bifidobacterium, exhibited reduced abundance in cancer patients. These findings suggest that some genera may serve as potential biomarkers for bladder cancer, highlighting the need for further research to explore their roles in disease pathogenesis and their potential applications in diagnostics and therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratoire de Biologie des Tumeurs Solides, Département de Pathologie et Oncobiologie, CHU Montpellier, Université de Montpellier, 34295 Montpellier, France.
- Montpellier BioInformatique pour le Diagnostic Clinique (MoBiDiC), Plateau de Médecine Moléculaire et Génomique (PMMG), CHU Montpellier, 34295 Montpellier, France.
- Institut du Cancer de Montpellier (ICM), Département de Biopathologie, 34295 Montpellier, France.
- Laboratoire de Bactériologie, CHU Montpellier, Université de Montpellier, 34295 Montpellier, France.
- Institut Régional du Cancer de Montpellier (IRCM), Université de Montpellier, ICM, Inserm, 34298 Montpellier, France.
ORCID-Profile: Simon Cabello-Aguilar, Steven Henry, Sylvain Godreuil, Jérôme Solassol
Zitieren
APA
Vendrell, J. A., Cabello-Aguilar, S., Senal, R., Heckendorn, E., Henry, S., Godreuil, S., & Solassol, J. (2024). Dysbiosis in Human Urinary Microbiota May Differentiate Patients with a Bladder Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251810159
Vancouver
Vendrell JA, Cabello-Aguilar S, Senal R, Heckendorn E, Henry S, Godreuil S, et al. Dysbiosis in Human Urinary Microbiota May Differentiate Patients with a Bladder Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251810159
BibTeX
@article{Vendrell2024,
author = {Vendrell, Julie A and Cabello-Aguilar, Simon and Senal, Romain and Heckendorn, Elise and Henry, Steven and Godreuil, Sylvain and Solassol, Jérôme},
title = {Dysbiosis in Human Urinary Microbiota May Differentiate Patients with a Bladder Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms251810159}
}
EUVIMED